He led one of the largest studies evaluating the immune response to influenza vaccination in pregnant women. In pregnant women, he studied the effectiveness of influenza and respiratory syncytial virus vaccines.
The paper provided one of the key pieces of evidence for the WHO recommendations of universal rotavirus vaccination. It was published in The New England Journal of Medicine in 2010. Madhi led the first study that showed that a rotavirus vaccine could significantly prevent severe diarrhoea during the first year of life in African babies.
This research led to the WHO recommendations on the delivery of this vaccine in low and middle-income countries. His research has included studies on the pneumococcal conjugate vaccine. In January 2021, he became Dean of the Faculty of Health Sciences of the University of the Witwateratand. In the same year he co-founded the African Leadership in Vaccinology Expertise (ALIVE), based at the University of the Witwatersrand, with the aim of expanding expertise in vaccinology in Africa. In 2018, after spending four years as deputy-chair of South Africa's National Advisory Group on Immunization (NAGI), he became its chairperson.
He was executive director of South Africa's National Institute for Communicable Diseases from 2011 to 2017, and has served on several WHO committees in roles pertinent to vaccines and pneumonia. These units have been rebranded as the MRC Vaccines and Infectious Diseases Analytics Research Unit (VIDA). Madhi is professor of vaccinology and director of the South African Medical Research Council Respiratory and Meningeal Pathogens Research Unit at the University of the Witwatersrand, and National Research Foundation/Department of Science and Technology Research Chair in Vaccine Preventable Diseases. In 1998 he received a master's degree in medicine (paediatrics). During this time, with encouragement from Glenda Gray, he applied for a post under professor Keith Klugman, to work on vaccines for pneumonia. In 1990 he completed his undergraduate and postgraduate training at the University of the Witwatersrand, Johannesburg, and six years later, became a fellow of the College of Paediatrics (FCPaeds (SA)). Initially aspiring to becoming an engineer, he opted to accept a bursary to study medicine and was initially reluctant to persist with his medical education. His father was a teacher and mother a housewife. In 2021 he stated that the first and foremost method of ending COVID-19 in South Africa is to implement a mass vaccination programme. Since the global COVID-19 pandemic in 2020, he has been leading COVID-19 vaccine trials in South Africa, including the first in Africa. His research has included studies on the pneumococcal conjugate vaccine and rotavirus vaccine, and in pregnant women, the influenza and respiratory syncytial virus vaccines. In 2018, he co-founded the African Leadership in Vaccinology Expertise (ALIVE) and was appointed Chair of South Africa's National Advisory Group on Immunization (NAGI). In January 2021, he was appointed Dean of the Faculty of Health Sciences at the University of the Witwateratand. Shabir Ahmed Madhi (born 1966) is a South African physician who is professor of vaccinology and director of the South African Medical Research Council Respiratory and Meningeal Pathogens Research Unit at the University of the Witwatersrand, and National Research Foundation/Department of Science and Technology Research Chair in Vaccine Preventable Diseases. Leading COVID-19 vaccine trials in South Africa University of the Witwatersrand, Johannesburg
0 kommentar(er)
